Logo image of PATH

UIPATH INC - CLASS A (PATH) Stock Fundamental Analysis

NYSE:PATH - US90364P1057 - Common Stock

11.12 USD
-0.14 (-1.24%)
Last: 8/29/2025, 8:04:01 PM
11.01 USD
-0.11 (-0.99%)
Pre-Market: 9/2/2025, 6:24:24 AM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PATH. PATH was compared to 280 industry peers in the Software industry. PATH has a great financial health rating, but its profitability evaluates not so good. PATH is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

PATH had positive earnings in the past year.
PATH had a positive operating cash flow in the past year.
PATH had negative earnings in each of the past 5 years.
In multiple years PATH reported negative operating cash flow during the last 5 years.
PATH Yearly Net Income VS EBIT VS OCF VS FCFPATH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

PATH has a Return On Assets (-2.55%) which is in line with its industry peers.
The Return On Equity of PATH (-3.97%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -2.55%
ROE -3.97%
ROIC N/A
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
PATH Yearly ROA, ROE, ROICPATH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

PATH has a better Gross Margin (82.62%) than 89.64% of its industry peers.
In the last couple of years the Gross Margin of PATH has remained more or less at the same level.
PATH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
PATH Yearly Profit, Operating, Gross MarginsPATH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
PATH has less shares outstanding than it did 1 year ago.
PATH has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PATH Yearly Shares OutstandingPATH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
PATH Yearly Total Debt VS Total AssetsPATH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

PATH has an Altman-Z score of 3.76. This indicates that PATH is financially healthy and has little risk of bankruptcy at the moment.
PATH has a Altman-Z score of 3.76. This is in the better half of the industry: PATH outperforms 62.86% of its industry peers.
PATH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.76
ROIC/WACCN/A
WACC11.28%
PATH Yearly LT Debt VS Equity VS FCFPATH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

PATH has a Current Ratio of 2.95. This indicates that PATH is financially healthy and has no problem in meeting its short term obligations.
PATH's Current ratio of 2.95 is fine compared to the rest of the industry. PATH outperforms 76.79% of its industry peers.
A Quick Ratio of 2.95 indicates that PATH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.95, PATH is in the better half of the industry, outperforming 77.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.95
PATH Yearly Current Assets VS Current LiabilitesPATH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

6

3. Growth

3.1 Past

PATH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.14%.
PATH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 88.99% yearly.
PATH shows a small growth in Revenue. In the last year, the Revenue has grown by 7.21%.
PATH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.58% yearly.
EPS 1Y (TTM)-7.14%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%-15.38%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%6.42%

3.2 Future

PATH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.84% yearly.
Based on estimates for the next years, PATH will show a quite strong growth in Revenue. The Revenue will grow by 11.61% on average per year.
EPS Next Y2.63%
EPS Next 2Y7.69%
EPS Next 3Y8.79%
EPS Next 5Y1.84%
Revenue Next Year9.45%
Revenue Next 2Y8.38%
Revenue Next 3Y8.77%
Revenue Next 5Y11.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PATH Yearly Revenue VS EstimatesPATH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
PATH Yearly EPS VS EstimatesPATH Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0.2 0.4 0.6

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 21.38, which indicates a rather expensive current valuation of PATH.
Compared to the rest of the industry, the Price/Earnings ratio of PATH indicates a somewhat cheap valuation: PATH is cheaper than 75.36% of the companies listed in the same industry.
PATH is valuated rather cheaply when we compare the Price/Earnings ratio to 27.13, which is the current average of the S&P500 Index.
PATH is valuated rather expensively with a Price/Forward Earnings ratio of 17.76.
80.36% of the companies in the same industry are more expensive than PATH, based on the Price/Forward Earnings ratio.
PATH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.76.
Industry RankSector Rank
PE 21.38
Fwd PE 17.76
PATH Price Earnings VS Forward Price EarningsPATH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

82.86% of the companies in the same industry are more expensive than PATH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 19.01
EV/EBITDA N/A
PATH Per share dataPATH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)8.14
PEG (5Y)N/A
EPS Next 2Y7.69%
EPS Next 3Y8.79%

0

5. Dividend

5.1 Amount

PATH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

UIPATH INC - CLASS A

NYSE:PATH (8/29/2025, 8:04:01 PM)

Premarket: 11.01 -0.11 (-0.99%)

11.12

-0.14 (-1.24%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-29 2025-05-29/amc
Earnings (Next)09-04 2025-09-04/amc
Inst Owners69.23%
Inst Owner Change21.04%
Ins Owners8.33%
Ins Owner Change0.26%
Market Cap5.95B
Analysts66
Price Target14.04 (26.26%)
Short Float %13.19%
Short Ratio5.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.23%
Min EPS beat(2)7.36%
Max EPS beat(2)27.1%
EPS beat(4)4
Avg EPS beat(4)25.4%
Min EPS beat(4)7.36%
Max EPS beat(4)47.41%
EPS beat(8)8
Avg EPS beat(8)46.66%
EPS beat(12)12
Avg EPS beat(12)102.69%
EPS beat(16)16
Avg EPS beat(16)98.69%
Revenue beat(2)1
Avg Revenue beat(2)1.34%
Min Revenue beat(2)-2.36%
Max Revenue beat(2)5.03%
Revenue beat(4)3
Avg Revenue beat(4)1.19%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)5.03%
Revenue beat(8)5
Avg Revenue beat(8)1%
Revenue beat(12)9
Avg Revenue beat(12)2.32%
Revenue beat(16)13
Avg Revenue beat(16)2.65%
PT rev (1m)-1.34%
PT rev (3m)15.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.36%
EPS NY rev (1m)0%
EPS NY rev (3m)0.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.63%
Valuation
Industry RankSector Rank
PE 21.38
Fwd PE 17.76
P/S 4.1
P/FCF 19.01
P/OCF 17.52
P/B 3.5
P/tB 3.83
EV/EBITDA N/A
EPS(TTM)0.52
EY4.68%
EPS(NY)0.63
Fwd EY5.63%
FCF(TTM)0.59
FCFY5.26%
OCF(TTM)0.63
OCFY5.71%
SpS2.71
BVpS3.17
TBVpS2.9
PEG (NY)8.14
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.55%
ROE -3.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.62%
FCFM 21.57%
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 170.17%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 2.95
Altman-Z 3.76
F-Score6
WACC11.28%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)72.19%
Cap/Sales(3y)1.29%
Cap/Sales(5y)1.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.14%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%-15.38%
EPS Next Y2.63%
EPS Next 2Y7.69%
EPS Next 3Y8.79%
EPS Next 5Y1.84%
Revenue 1Y (TTM)7.21%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%6.42%
Revenue Next Year9.45%
Revenue Next 2Y8.38%
Revenue Next 3Y8.77%
Revenue Next 5Y11.61%
EBIT growth 1Y38.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.51%
EBIT Next 3Y26.99%
EBIT Next 5Y22.63%
FCF growth 1Y232.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y208.1%
OCF growth 3YN/A
OCF growth 5YN/A